FDA Approves New Formulation of Hyrimoz Adalimumab Biosimilar FDA Approves New Formulation of Hyrimoz Adalimumab Biosimilar

The agency approved a higher concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.Medscape Medical News
Source: Medscape Pediatrics Headlines - Category: Pediatrics Tags: Rheumatology News Alert Source Type: news